Simponi - Golimumab - Dosage - Side Effects - Interactions - Warnings
- A - Z: Biologics / Blockers
- A - Z: Lower Drug Costs
- Ankylosing Spondylitis
- Needlephobia Overview
- Psoriatic Arthritis
- Rheumatoid Arthritis
Simponi (golimumab) - What You Should Know
Simponi (golimumab) is a TNF-alpha blocker administered monthly to treat rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
TNF Blockers - What You Need to Know
The first TNF blocker, Enbrel, was marketed in 1998. Simponi is one of the newest TNF blockers.
Fungal Infection - A Risk With TNF-alpha Blockers
The FDA has announced that the makers of four TNF-alpha drugs must strengthen warnings about fungal infection.
Can TNF Blockers Be Stopped When Remission Is Achieved?
TNF blockers -- Enbrel, Remicade, and Humira -- are biologic drugs with the potential for slowing the progression of rheumatoid arthritis and other inflammatory types of arthritis. If remission is achieved, can TNF blockers be stopped?
Is Infection a Serious Side Effect of DMARDs and Biologic Drugs?
Some patients are prone to infection while being treated with DMARDs or biologic drugs. Is infection a serious side effect of biologic drugs? What can be done to fight off infection?
Are Some Arthritis Patients Unsuitable Candidates For Biologic Drugs?
Simponi is one of the biologic drugs used to treat inflammatory types of arthritis.